Zim Laboratories Ltd. · NSE:ZIMLAB
Zim Laboratories — Q1 FY27 Earnings Presentation
19 slides from Zim Laboratories's earnings presentation, August 2026
Slide 1: Zim Laboratories Limited Earnings Presentation Q1 FY27
ZIM LABORATORIES LIMITED Zeal & Innovation in Medicine E A R N I N G S P R E S E N T A T I O N Q1 FY27 People Innovation Quality www.zimlab.in
Slide 2: Safe Harbour
SAFE HARBOUR The presentation has been prepared by ZIM Laboratories Limited ("ZIM" or the "Company") solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall f
Slide 3: Table of Content
Table of Content Q1 FY27 Highlights 01 Financial performance snapshot for the quarter 02 Financial Performance Q1 FY27 Revenue, EBITDA, margins and R&D investment trends 03 Business Mix Product and market mix driving the revenue profile 04 R&D & Innovation NIP & OTF pipeline progress, approvals and
Slide 4: Q1 FY27 Financial Highlights
Q1 FY27 FINANCIAL HIGHLIGHTS Q1 FY27 Vs Q1 FY26 Total Operating Income ₹942 Mn ₹718 Mn ▲ 31.2% EBITDA ₹34 Mn ₹57 Mn ▼ 40.0% EBITDA Margin 3.7% 7.9% ▼ 430 bps Total R&D Spend* ₹82 Mn 8.7% of TOI *Incl. ₹34 Mn towards BE studies & regulatory filings 4
Slide 5: Regulatory Momentum (Q1 FY27)
REGULATORY MOMENTUM (Q1 FY27) F il i ng s & Ap pr ov al s FILED W ITH M OH M As R ECEIV ED F R OM M OH NI P OD S FF NI P OD S FF 2 9 6 4 3 3 New Innovative Oral Thin Finished Formulations New Innovative Oral Thin Finished Formulations Products Films Generic Products Films Generic 17 10 3 NIP · ODS ·
Slide 6: Status Update & Progress on EU-GMP CAPA Remediation
STATUS UPDATE & PROGRESS ON EU-GMP CAPA REMEDIATION Most of the CAPA remediation plan has been completed and implemented Q2 FY26 June / July EU GMP Inspection. Onboarding External Consultant for CAPA Plan. Submission 01 of comprehensive CAPA Remediation Plan. Capital Expenditure Orders placed for ke
Slide 7: Total Operating Income
TOTAL OPERATING INCOME Total Operating Income (₹Mn) 1,087 1,053 942 887 718 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 ₹ Mn • Total Operating Income at ₹942 Mn, up 31.2% YoY • Total Operating Income down 10.5% QoQ due to war situation in the Mid East and serious logistic challenges; some early signs of
Slide 8: EBITDA & EBITDA %
EBITDA & EBITDA % EBITDA & EBITDA Margin 13.4% 12.7% EBITDA Margin 8.8% 7.9% ₹ Mn 145 134 3.7% 78 57 34 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 EBITDA EBITDA Margin • EBITDA at ₹34 Mn, down 40% YoY; EBITDA margins at 3.7% vs 7.9% in Q1 FY26. • Gross contribution margins remained in line with margins
Slide 9: Expense Bridge: Q1 FY26 to Q1 FY27
EXPENSE BRIDGE: Q1 FY26 → Q1 FY27 Employee benefits & other operating expenses · ₹ Mn Q1 FY26 total Employee ↑ Opex ↑ Others ↑ Q1 FY27 total 337 +72 +41 +17 467 +2.0 +7.0 +15.0 +7.0 +16.0 +18.0 +26.0 +10.0 +28.0 ₹ Mn 467 337 9
Slide 10: PAT & PAT %
PAT & PAT % PAT & PAT Margin 4.0% 3.6% 44 37 PAT Margin ₹ Mn (4) Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 (19) -0.5% (40) -2.6% -4.3% PAT PAT Margin • PAT at ₹ (40 Mn) in Q1 FY27 declined from ₹(19) Mn in Q1 FY26 ; mainly due to flow through of lower EBITDA. • Increase in depreciation and finance cos
Slide 11: Pharmaceutical & Nutraceutical: Mix %
PHARMACEUTICAL & NUTRACEUTICAL : MIX % Pharma vs Nutra - Quarterly Revenue (₹ Mn) & Pharma Mix (%) 82% 72% 87% 82% 77% 78% 71% 196 141 72% 300 67% 224 268 155 268 Revenue (₹ Mn) Pharma Mix % 266 157 891 911 786 739 732 654 673 552 560 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q
Slide 12: Innovative Product Contribution
INNOVATIVE PRODUCT CONTRIBUTION (NIP + OTF) Revenue (₹ Mn) & Contribution to Total Operating Income (%) 21% 22% 65 % of Total Operating Income 18% 26 15% 14% 14% 45 12% ₹ Mn 59 37 56 9% 74 152 6% 155 119 39 101 78 88 34 58 42 12 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27
Slide 13: Business Mix
BUSINESS MIX Business Mix (₹ Mn) & Export (%) 88% 82% 84% 17 84% 82% 109 38 156 26 32 124 127 16 Export (%) 100 ₹ Mn 961 859 792 728 602 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Export Domestic Deemed Export Export (%) • Export business share is at 84% of revenue in Q1 FY27 • Export Business increase
Slide 14: Advancing Innovation: NIP Product Pipeline (EU/UK)
ADVANCING INNOVATION : NIP PRODUCT PIPELINE (EU/UK) 12 products in active development across 7 therapy areas - 3 regulatory approvals secured · Several products ready for filing Therapy Market Formulation BE Reg. Reg. Commercial Product Validation Area Review Dev. Studies Filing Approval Supplies Pr
Slide 15: Advancing Innovation: OTF Product Pipeline (EU/UK)
ADVANCING INNOVATION : OTF PRODUCT PIPELINE (EU/UK) 5 OTF products across 3 therapy areas - 3 regulatory approvals secured Therapy Market Formulation BE Reg. Reg. Commercial Product Validation Area Review Dev. Studies Filing Approval Supplies Rizatriptan CNS Erectile Sildenafil Dysfunction Product 3
Slide 16: R&D Driving Product Innovation
R&D DRIVING PRODUCT INNOVATION R&D EXPENSE MIX & INVESTMENT AS % OF OPERATING INCO ME Q1 FY27 : ₹34 Mn 11% 8.7% allocated for BE studies & registrations, advancing the Innovative Products 24% Capital Expenses on BE-Study & (NIP + OTF) pipeline 41% Registration etc 12% Capital Expenses on 1% Infrastr
Slide 17: Income Statement
INCOME STATEMENT Particulars (₹ Mn) Q1FY27 Q1FY26 YoY% Q4FY26 QoQ% Total Operating Income 942 718 31.2% 1,053 -10.5% Other Income 10 15 -32.8% 62 -84.0% Total Income 952 733 30.0% 1,115 -14.6% EBITDA 34 57 -40.0% 134 -74.2% EBITDA % 3.7% 7.9% (430) Bps 12.7% (900) Bps Finance Cost 36 33 10.3% 33 10.
Slide 18: Shareholding
SHAREHOLDING Ownership % (June 2026) Traded Volume (In K) - BSE + NSE 26,593 4.6 18,435 30.3 16,660 26.2 14,104 11,313 11,016 5,734 6,187 5,048 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 38.8 Traded Volume (K) Promoter Other Public Body Corporates NRI & Foreign Shareholders : 14.
Slide 19: Investor Relations & Contact
Zeal & I nnovation in Medicine · Z iM Laboratories Limited · Nagpur, Maha rashtra Mr. Zain Daud ZIM Laboratories Limited INVESTOR RELATIONS & CONTACT zain.daud@zimlab.in +91 9022 434631 Ms. Deepika Sharma Ms. Priya Sen Ms. Sheetal Khanduja Address : Sadoday Gyan (Ground Floor), Go India Advisors Go